Epidermal growth factor receptor (EGFR) inhibitors are an increasingly important treatment
option for metastasized cancer in patients. In addition to the pivotal role of EGFR in the …

Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of
cancers such as non-small cell lung cancer, head and neck cancer, breast cancer …

The epidermal growth factor receptor (EGFR) is often overexpressed or dysregulated in solid
tumors. Targeting the EGFR-mediated signaling pathway has become routine practice in the …

Epidermal growth factor receptor (EGFR) inhibitors are associated with unique and dramatic
dermatologic side effects. Cetuximab, erlotinib, and gefitinib have been approved for …

A relatively newer class of chemotherapy agents, known as the epidermal growth factor
receptor inhibitors (EGF-RIs), is being used to treat advanced stages of solid tumors …

Although the field continues to evolve, this review presents the most up-to-date information
on managing dermatologic adverse effects of EGFRIs. Practitioners should find this article to …

BACKGROUND: Epidermal growth factor receptor (EGFR) inhibitors frequently result in
dermatologic toxicities, including rash, xerosis, pruritus, and paronychia. Although the …

The use of epidermal growth factor receptor (EGFR) inhibitors for the treatment of solid
tumours is increasing. However, the tolerability profile for EGFR‐inhibitors, such as the …

Purpose Cutaneous adverse events induced by epidermal growth factor receptor (EGFR)
inhibitors can hamper the patients' quality of life. The aim of our work was to draft an …

Epidermal growth factor receptor inhibitors (EGFRIs) have demonstrated improved overall
survival in patients with non-small cell lung cancer, pancreatic cancer, and colorectal …